Copyright © 2018 UCSD ADRC.
All rights reserved.


Normal Control

Research Opportunities


Research Registry

If you are interested in any of the studies listed below or if you are interested in participating in a research study but don't currently see one that suits you, you can now join our research registry to be placed on a list for future studies. 

*Call the ADRC 858-822-4800 and ask for Tracey Truscott, LCSW for more information about research participation or being added to our registry.


Currently Enrolling New Participants

Observational Studies


PI: James Brewer, MD, PhD, Douglas Galasko, MD, and David Salmon, PhD           

CONTACT: Tracey Truscott, LCSW (858) 822-4800 or                 

TIME INVOLVED: minimum 5 years                                                                                                                                        

DESCRIPTION: The purpose of this study is to learn how the brain changes as we age. This is an observational study with no medication, with behavioral, medical, and cognitive data collection and testing as well as a neurological exam. This is done annually from the time of enrollment to death. Information about strategies for healthy brain aging is provided, as is feedback about one’s annual performance on cognitive testing. We continue to obtain blood and CSF samples to match up changes in chemicals we can measure in the blood and CSF with changes in cognition and brain structure.                                      

REQUIREMENTS: Age 65 and older if normal cognition or diagnosis of MCI or early dementia due to Alzheimer’s, FTD, or DLB; study partner; LP and MRI required; brain autopsy required.

For the study brochure in English, click here

For the study brochure in Spanish, click here


PI: James Brewer, MD, PhD      

CONTACT: Mollie Paster, (858) 822-4800

TIME INVOLVED: minimum 5 years                                                                                                                                                    

DESCRIPTION: The primary goal is to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in ongoing Alzheimer’s disease research. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) plays a central role in improving treatment trials. Since the study’s launch, ADNI Investigators with regulators in both the US and abroad have facilitated the design of major completed and ongoing drug trials. ADNI 3 is a continuation of this work. ADNI 3 is a non-randomized, natural history, non-treatment study. Clinical/cognitive, imaging (MRI and PET scans), biomarker, and genetic characteristics will be assessed across the three cohorts: Normal controls (NC), Mild Cognitive Impairment (MCI), and mild Alzheimer’s disease (AD). Visits will occur annually for MCI and AD subjects and biennially for NC subjects.               

REQUIREMENTS: Age 55-90; have normal cognition or a diagnosis of MCI, or AD; have a study partner; have overall good general health. Subjects are required to undergo MRI and PET scans and undergo a lumbar puncture.